Table 1. Possible clinical trials.

Hypothesis	Study population	Intervention	Outcomes of interest
Early intervention in patients with primary MR might improve clinical outcomes and prevent MR-related complications.	Asymptomatic patients with primary severe MR who are at high risk for surgical mitral valve repair with anatomical suitability for TEER	TEER versus medical therapy	Clinical outcomes, mortality, hospitalisations, AFib burden, and pulmonary artery pressures
Early intervention in post-MI MR might improve clinical outcomes and prevent adverse LV remodelling.	Symptomatic patients with severe MR within 90 days after acute MI	TEER versus medical therapy	Clinical outcomes, mortality, hospitalisations, and LV remodelling parameters
Mitral intervention among patients with atrial myopathy might prevent adverse LA myopathy and remodelling.	Patients with atrial myopathy and paroxysmal AFib and secondary severe atrial MR	TEER versus medical therapy/AFib ablation	Clinical outcomes, mortality, hospitalisations, LA remodelling parameters, and AFib burden
AFib: atrial fibrillation; HF: heart failure; LA: left atrial; LV: left ventricular; MI: myocardial infarction; MR: mitral regurgitation; TEER: transcatheter mitral edge-to-edge repair